Pfizer Inc (PFE)-Medical Equipment-Deals and Alliances Profile

Pfizer Inc (PFE)-Medical Equipment-Deals and Alliances Profile


  • Products Id :- GDME32190D
  • |
  • Pages: 166
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

Pfizer Inc (Pfizer) is a biopharmaceutical company, which focuses on the discovery, development, manufacture and marketing of healthcare products. It provides medicines, vaccines and consumer healthcare products. The company provides products in key therapeutic areas including internal medicine, cancer, vaccines, inflammation and immunology and rare diseases. It also provides sterile injectable pharmaceuticals, infusion systems, biosimilars, as well as active pharmaceutical ingredients (APIs) and contract manufacturing services. Pfizer sells prescription pharmaceutical products through wholesalers, besides selling them directly to retailers, hospitals, clinics, government agencies and pharmacies. It sells consumer healthcare products through pharmacies, retail chains, distributors and grocery and convenience stores. The company provides its products in the US, Canada, Latin America, Asia, Japan, South Korea, New Zealand, Australia, Finland, Scandinavian countries, Africa, the Middle East and Turkey. Pfizer is headquartered in New York, the US.

Pfizer Inc (PFE)-Medical Equipment-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

Business Description-A brief description of the company's operations.

Key Employees-A list of the key executives of the company.

Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

Key Competitors-A list of the key competitors of the company.

Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 7

Pfizer Inc, Medical Equipment, Deals By Year, 2011 to YTD 2017 8

Pfizer Inc, Medical Equipment Deals By Type, 2011 to YTD 2017 9

Pfizer Inc, Medical Equipment, Deals By Region, 2011 to YTD 2017 10

Pfizer Inc, Medical Equipment, Deals By Market, 2011 to YTD 2017 11

Pfizer Inc, Medical Equipment, Deals Summary, 2011 to YTD 2017 12

Pfizer Inc, Medical Equipment, Deal Details 17

Venture Financing 17

Neuronetics Raises USD15 Million in Series G Round of Financing 17

Cordex Systems Raises Funds in Series A Financing 18

Advanced MR Analytics Raises USD9 Million in Venture Financing 20

Molecular Stethoscope Raises USD8.2 Million in Seed Financing 21

RefleXion Medical Raises Additional USD6 Million in Series B Financing 21

RefleXion Medical Raises USD46 Million in Series B Financing 22

UE LifeSciences to Raise USD0.1 Million in Seed Financing 23

RefleXion Medical Raises US$11.6 Million In Series A Round 24

NeuMoDx Raises US$21 Million In Series B Financing 25

Nodality Raises US$15 Million In Venture Financing Round 26

InnoPharma Secures US$15 Million In Series A Financing Round 27

Neuronetics Secures US$30 Million In Series E Financing 28

U-Systems Secures US$6.5 Million In Venture Financing Round 30

Partnerships 31

Pfizer Enters into Licensing Agreement with Scripps Research Institute 31

Pfizer Enters into Licensing Agreement with Pelago Bioscience 32

Ichor Medical Systems Enters Into Licensing Agreement With Pfizer 32

pSivida Amends Licensing Agreement With Pfizer 33

Mirth Enters Into Licensing Agreement With Pfizer Health Solutions 34

InSphero Enters into Agreement with Pfizer 35

Molecular Stethoscope Enters into Research Agreement with Pfizer 36

Iatric Systems Enters into Agreement with Hospira 36

Pfizer Enters into Distribution Agreement Adhezion Biomedical 37

Pfizer Enters into Research Agreement with International Business Machines 38

Medivation and NanoString Technologies Enter into Partnership With Astellas Pharma 39

Thermo Fisher Scientific Enters into Agreement with Novartis and Pfizer 40

Merck and Pfizer Enters into Agreement with Dako 41

Pfizer Enters into Evaluation Agreement with BIRAD 42

Thermo Fisher Scientific Enters into Co-Development Agreement with GlaxoSmithKline and Pfizer 42

Siemens Healthcare Enters Into Co-Development Agreement With Pfizer 44

Protagen Enters Into Biomarker Discovery Agreement With Pfizer 45

MaRS Innovation Enters Into Partnership With Pfizer 45

Dako Enters Into Agreement With Pfizer For Companion Diagnostics 46

Hospira Enters Into Distribution Agreement With Q Core Medical For Sapphire Infusion System 47

Humedica Enters Into Agreement With Pfizer 48

Stellar Pharma Enters Into Co-Marketing Agreement With Pfizer Canada For Gelfoam 49

Ventana Medical Systems Enters Into Co-Development Agreement With Pfizer 49

ICU Medical Extends Distribution Agreement With Hospira For CLAVE And Oncology Products 50

ICU Medical Extends Distribution Agreement With Hospira For Infusion Sets 51

Qiagen Enters Into Co-Development Agreement With Pfizer 52

Resonance Health Enters into Agreement with Pfizer 53

Mylan Specialty Enters Into Licensing Agreement With Pfizer For EpiPen 54

Abbott Labs Enters Into Licensing Agreement With Pfizer 55

Kiadis Pharma Enters Into Licensing Agreement With Hospira For ATIR 55

Debt Offering 56

Pfizer Raises USD1.06 Billion in Private Placement of 4.2% Notes Due 2047 56

Pfizer Raises USD1.3 Billion in Public Offering of Notes Due 2019 58

Pfizer Raises USD793.5 Million in Public Offering of 1% Notes Due 2027 59

Pfizer Raises USD1.06 Billion in Public Offering of Notes Due 2020 61

Pfizer Raises USD1.06 Billion in Public Offering of 0.25% Notes Due 2022 62

Pfizer Raises USD1.3 Billion in Public Offering of 4.125% Notes Due 2046 64

Pfizer Raises USD1 Billion in Public Offering of 1.7% Notes Due 2019 66

Pfizer Raises USD1 Billion in Public Offering of 4% Notes Due 2036 67

Pfizer Raises USD1 Billion in Public Offering of 2.2% Notes Due 2021 69

Pfizer Raises USD1.8 Billion in Public Offering of 3% Notes Due 2026 71

Pfizer Raises USD0.85 Billion in Public Offering of 1.45% Notes Due 2019 73

Pfizer Raises USD1.25 Billion in Public Offering of 2.75% Notes Due 2026 74

Pfizer Raises USD1.25 Billion in Public Offering of 1.2% Notes Due 2018 76

Pfizer Raises USD0.5 Billion in Public Offering of 4.4% Notes Due 2044 77

Pfizer Raises USD1.15 Billion in Public Offering of 1.95% Notes Due 2021 79

Asset Transactions 81

ICU Medical Acquires Hospira Infusion Systems Business from Pfizer 81

Mylan Completes Acquisition Of Respiratory Delivery Platform From Pfizer For US$348 Million 82

True Process Acquires VeriScan, Bar Code And Radio-Frequency Identification System From Hospira 84

Acquisition 84

Pfizer Acquires Hospira for USD17 Billion 84

Pfizer May Acquire Remaining 90.5% Stake in Cellectis 87

Pfizer May Increase Bid to Acquire AstraZeneca 87

Premier Acquires TheraDoc from Hospira for USD117 Million 89

Fluidigm Completes Acquisition Of DVS Sciences For US$207.5 Million 90

Abbott, Johnson & Johnson And Sanofi Mull Individual Acquisition Of Bausch & Lomb 92

Covidien Completes Acquisition Of superDimension, Pulmonary Device Maker, For US$300 Million 94

Pfizer Inc-Key Competitors 97

Key Employees 98

Locations And Subsidiaries 100

Head Office 100

Other Locations & Subsidiaries 100

Recent Developments 127

Strategy And Business Planning 127

Jun 27, 2017: Pfizer Breaks Ground on New R&D Facility in Chesterfield, Missouri 127

Sep 26, 2016: Pfizer Decides Remaining One Company Best Positions Company To Maximize Future Value Creation 128

Jul 13, 2016: Pfizer and NovaMedica announce a strategic partnership in Russia 129

Jun 16, 2016: Pfizer Breaks Ground On New Biologics Clinical Manufacturing Facility In Andover, Massachusetts 130

Financial Announcements 131

May 02, 2017: Pfizer Reports First-Quarter 2017 Results 131

Jan 31, 2017: Pfizer Reports Fourth-Quarter And Full-Year 2016 Results 135

Nov 01, 2016: Pfizer Reports Third-Quarter 2016 Results 140

Aug 02, 2016: Pfizer Reports Second-Quarter 2016 Results 145

May 03, 2016: Pfizer Reports First-Quarter 2016 Results 149

Feb 02, 2016: Pfizer Reports Fourth-Quarter And Full-Year 2015 Results Provides 2016 Financial Guidance 153

Corporate Communications 158

Jun 28, 2017: Pfizer breaks ground on new R&D facility in Missouri 158

Feb 23, 2017: Ronald E. Blaylock Elected to Pfizer's Board of Directors 159

Nov 21, 2016: Anthony J. Maddaluna, Executive Vice President and President of Pfizer Global Supply to Retire 160

Sep 07, 2016: Pfizer Appoints Chief Scientific Officer for Neuroscience Research 161

Feb 08, 2016: Pfizer Names Executive Leadership Team for Combined Organization Upon Close of Proposed Allergan Transaction 162

Legal and Regulatory 163

Apr 27, 2016: A.G. Schneiderman Announces Multistate And Federal Settlement With Wyeth And Pfizer For $784.6m To Resolve Allegations Of Underpaying Rebates Owed Through The Medicaid Drug Rebate Program 163

Mar 22, 2016: Geisinger Health System receives accreditation from the Association for the Accreditation of Human Research Protection Programs 165

Appendix 166

Methodology 166

About GlobalData 166

Contact Us 166

Disclaimer 166

List of Figures

Pfizer Inc, Medical Equipment, Deals by Type, 2011 to YTD 2017 1

Pfizer Inc, Medical Equipment, Deals By Year, 2011 to YTD 2017 1

Pfizer Inc, Medical Equipment, Deals By Region, 2011 to YTD 2017 1

Pfizer Inc, Medical Equipment, Deals By Market, 2011 to YTD 2017 1

Pfizer Inc, Medical Equipment, Deals By Year, 2011 to YTD 2017 8

Pfizer Inc, Medical Equipment, Deals by Type, 2011 to YTD 2017 9

Pfizer Inc, Medical Equipment, Deals By Region, 2011 to YTD 2017 10

Pfizer Inc, Medical Equipment, Deals by Market, 2011 to YTD 2017 11

List of Tables

Pfizer Inc, Medical Equipment, Key Facts, 2016 1

Pfizer Inc, Medical Equipment, Deals Summary, 2011 to YTD 2017 1

Pfizer Inc, Medical Equipment, Deals By Year, 2011 to YTD 2017 8

Pfizer Inc, Medical Equipment Deals By Type, 2011 to YTD 2017 9

Pfizer Inc, Medical Equipment, Deals By Region, 2011 to YTD 2017 10

Pfizer Inc, Deals By Market, 2011 to YTD 2017 11

Pfizer Inc, Medical Equipment, Deals Summary, 2011 to YTD 2017 12

Neuronetics Raises USD15 Million in Series G Round of Financing 17

Cordex Systems Raises Funds in Series A Financing 18

Advanced MR Analytics Raises USD9 Million in Venture Financing 20

Molecular Stethoscope Raises USD8.2 Million in Seed Financing 21

RefleXion Medical Raises Additional USD6 Million in Series B Financing 21

RefleXion Medical Raises USD46 Million in Series B Financing 22

UE LifeSciences to Raise USD0.1 Million in Seed Financing 23

RefleXion Medical Raises US$11.6 Million In Series A Round 24

NeuMoDx Raises US$21 Million In Series B Financing 25

Nodality Raises US$15 Million In Venture Financing Round 26

InnoPharma Secures US$15 Million In Series A Financing Round 27

Neuronetics Secures US$30 Million In Series E Financing 28

U-Systems Secures US$6.5 Million In Venture Financing Round 30

Pfizer Enters into Licensing Agreement with Scripps Research Institute 31

Pfizer Enters into Licensing Agreement with Pelago Bioscience 32

Ichor Medical Systems Enters Into Licensing Agreement With Pfizer 32

pSivida Amends Licensing Agreement With Pfizer 33

Mirth Enters Into Licensing Agreement With Pfizer Health Solutions 34

InSphero Enters into Agreement with Pfizer 35

Molecular Stethoscope Enters into Research Agreement with Pfizer 36

Iatric Systems Enters into Agreement with Hospira 36

Pfizer Enters into Distribution Agreement Adhezion Biomedical 37

Pfizer Enters into Research Agreement with International Business Machines 38

Medivation and NanoString Technologies Enter into Partnership With Astellas Pharma 39

Thermo Fisher Scientific Enters into Agreement with Novartis and Pfizer 40

Merck and Pfizer Enters into Agreement with Dako 41

Pfizer Enters into Evaluation Agreement with BIRAD 42

Thermo Fisher Scientific Enters into Co-Development Agreement with GlaxoSmithKline and Pfizer 42

Siemens Healthcare Enters Into Co-Development Agreement With Pfizer 44

Protagen Enters Into Biomarker Discovery Agreement With Pfizer 45

MaRS Innovation Enters Into Partnership With Pfizer 45

Dako Enters Into Agreement With Pfizer For Companion Diagnostics 46

Hospira Enters Into Distribution Agreement With Q Core Medical For Sapphire Infusion System 47

Humedica Enters Into Agreement With Pfizer 48

Stellar Pharma Enters Into Co-Marketing Agreement With Pfizer Canada For Gelfoam 49

Ventana Medical Systems Enters Into Co-Development Agreement With Pfizer 49

ICU Medical Extends Distribution Agreement With Hospira For CLAVE And Oncology Products 50

ICU Medical Extends Distribution Agreement With Hospira For Infusion Sets 51

Qiagen Enters Into Co-Development Agreement With Pfizer 52

Resonance Health Enters into Agreement with Pfizer 53

Mylan Specialty Enters Into Licensing Agreement With Pfizer For EpiPen 54

Abbott Labs Enters Into Licensing Agreement With Pfizer 55

Kiadis Pharma Enters Into Licensing Agreement With Hospira For ATIR 55

Pfizer Raises USD1.06 Billion in Private Placement of 4.2% Notes Due 2047 56

Pfizer Raises USD1.3 Billion in Public Offering of Notes Due 2019 58

Pfizer Raises USD793.5 Million in Public Offering of 1% Notes Due 2027 59

Pfizer Raises USD1.06 Billion in Public Offering of Notes Due 2020 61

Pfizer Raises USD1.06 Billion in Public Offering of 0.25% Notes Due 2022 62

Pfizer Raises USD1.3 Billion in Public Offering of 4.125% Notes Due 2046 64

Pfizer Raises USD1 Billion in Public Offering of 1.7% Notes Due 2019 66

Pfizer Raises USD1 Billion in Public Offering of 4% Notes Due 2036 67

Pfizer Raises USD1 Billion in Public Offering of 2.2% Notes Due 2021 69

Pfizer Raises USD1.8 Billion in Public Offering of 3% Notes Due 2026 71

Pfizer Raises USD0.85 Billion in Public Offering of 1.45% Notes Due 2019 73

Pfizer Raises USD1.25 Billion in Public Offering of 2.75% Notes Due 2026 74

Pfizer Raises USD1.25 Billion in Public Offering of 1.2% Notes Due 2018 76

Pfizer Raises USD0.5 Billion in Public Offering of 4.4% Notes Due 2044 77

Pfizer Raises USD1.15 Billion in Public Offering of 1.95% Notes Due 2021 79

ICU Medical Acquires Hospira Infusion Systems Business from Pfizer 81

Mylan Completes Acquisition Of Respiratory Delivery Platform From Pfizer For US$348 Million 82

True Process Acquires VeriScan, Bar Code And Radio-Frequency Identification System From Hospira 84

Pfizer Acquires Hospira for USD17 Billion 84

Pfizer May Acquire Remaining 90.5% Stake in Cellectis 87

Pfizer May Increase Bid to Acquire AstraZeneca 87

Premier Acquires TheraDoc from Hospira for USD117 Million 89

Fluidigm Completes Acquisition Of DVS Sciences For US$207.5 Million 90

Abbott, Johnson & Johnson And Sanofi Mull Individual Acquisition Of Bausch & Lomb 92

Covidien Completes Acquisition Of superDimension, Pulmonary Device Maker, For US$300 Million 94

Pfizer Inc, Key Competitors 97

Pfizer Inc, Key Employees 98

Pfizer Inc, Subsidiaries 100

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Pfizer Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license

Single User License
USD 250 INR 16088
Site License
USD 500 INR 32175
Corporate User License
USD 750 INR 48263

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com